von Tobias Borgers | Okt. 8, 2019 | Bayer
The FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s rival Eylea on price per dose but reduce costs with a less frequent dosing regimen.Novartis’ Beovu (brolucizumab) has matched the performance...
von Tobias Borgers | Sep. 27, 2019 | Bayer
Bayer: Investitionen in die Zukunft – auf diese Chartmarken sollten Sie jetzt achten! DER AKTIONÄR Link zum Originalbeitrag
von Tobias Borgers | Sep. 20, 2019 | Bayer
Bayer Tops Worldcom’s Digital Health Monitor For The Pharma Sector Business WireResearch executed by The Worldcom Public Relations Group, suggests many large pharmaceutical companies are not optimizing online and social media. Link zum...
von Tobias Borgers | Sep. 16, 2019 | Bayer
Bayer completes merger of Monsanto India Times of IndiaIndia Business News: New Delhi, Sep 16 () German chemical and pharma major Bayer AG on Monday said it has completed the integration of biotech major … Link zum...
von Tobias Borgers | Sep. 3, 2019 | Bayer
Bayer hires former J&J executive for more pharma deals ReutersBayer nabs new dealmaker – but after Monsanto, is there enough cash? FierceBiotechBayer appoints Marianne De Backer Head of Pharmaceuticals Business Development &...
von Tobias Borgers | Aug. 28, 2019 | Bayer
GREENFIELD, Ind. — Elanco Animal Health acquired Bayer Animal Health Aug. 20 in a transaction valued at $7.6 billion.The purchase positions Elanco as the second largest animal health company in the world.“This acquisition strengthens and accelerates our focused...
